Extent and cost of inappropriate use of tumour markers in patients with pulmonary disease: a multicentre retrospective study in Shanghai, China

Abstract

ObjectivesThe currently implemented healthcare reform in China requires substantial capital investment. Although overtreatment results in serious waste, inappropriate laboratory use is widespread, and overuse of tumour markers (TMs) has attracted increasing attention.DesignRetrospective study.SettingThe respiratory, thoracic surgery and oncology departments of three hospitals in Shanghai from 2014 to 2015.ParticipantsPatients with chronic obstructive pulmonary disease (COPD) and primary bronchogenic lung cancer (PLC). Based on clinical guidelines and physician experience, the criteria of suitability of TM examinations were determined, and the number, cost and proportion of inappropriate TM requests were analysed.ResultsThe area under the receiver operating characteristic curve for carcinoembryonic antigen+cytokeratin fragment 21-1+squamous cell carcinoma antigen+neuron-specific enolase in patients with COPD and PLC was 0.813, in accordance with the cost-effectiveness principle, indicating good clinical and health economics values. In the 2706 patients, 12 496–16 956 (58.27%–79.06%) of TM requests were inappropriate. Furthermore, the involved expense was 650 200–1 014 156 yuan, accounting for 7.69%–12.00% of examination expenses and 1.35%–2.11% of hospitalisation costs.ConclusionsWe found that the inappropriate use of TMs was widespread for patients with pulmonary disease. Clinicians should use TMs strictly according to the guidelines to effectively manage laboratory resources and control costs.